Zhou Zezhen, Deng Shaohui, Yan Ye, Zhang Fan, Hao Yichang, Ge Liyuan, Zhang Hongxian, Wang Guoliang, Zhang Shudong
Department of Urology, Peking University Third Hospital, Beijing 100191, China.
Beijing Da Xue Xue Bao Yi Xue Ban. 2024 Aug 18;56(4):673-679. doi: 10.19723/j.issn.1671-167X.2024.04.021.
To predict the 3-year cancer-specific survival (CSS) of patients with non-metastatic T renal cell carcinoma after surgery.
A total of 336 patients with pathologically confirmed T N0-1M0 renal cell carcinoma (RCC) who underwent surgical treatment at the Department of Urology, Peking University Third Hospital from March 2013 to February 2021 were retrospectively collected. The patients were randomly divided into a training cohort of 268 cases and an internal validation cohort of 68 cases at an 4 ∶ 1 ratio. Using two-way Lasso regression, variables were selected to construct a nomogram for predicting the 3-year cancer-specific survival (CSS) of the patients with TN0-1M0 RCC. Performance assessment of the nomogram included evaluation of discrimination and calibration ability, as well as clinical utility using measures such as the concordance index (C-index), time-dependent area under the receiver operating characteristic curve [time-dependent area under the curve (AUC)], calibration curve, and decision curve analysis (DCA). Risk stratification was determined based on the nomogram scores, and Kaplan-Meier survival analysis and Log-rank tests were employed to compare progression-free survival (PFS) and cancer-specific survival (CSS) among the patients in the different risk groups.
Based on the Lasso regression screening results, the nomogram was constructed with five variables: tumor maximum diameter, histological grading, sarcomatoid differentiation, T feature, and lymph node metastasis. The baseline data of the training and validation sets showed no statistical differences (>0.05). The consistency indices of the column diagram were found to be 0.808 (0.708- 0.907) and 0.903 (0.838-0.969) for the training and internal validation sets, respectively. The AUC values for 3-year cancer-specific survival were 0.843 (0.725-0.961) and 0.923 (0.844-1.002) for the two sets. Calibration curves of both sets demonstrated a high level of consistency between the actual CSS and predicted probability. The decision curve analysis (DCA) curves indicated that the column diagram had a favorable net benefit in clinical practice. A total of 336 patients were included in the study, with 35 cancer-specific deaths and 69 postoperative recurrences. According to the line chart, the patients were divided into low-risk group (scoring 0-117) and high-risk group (scoring 119-284). Within the low-risk group, there were 16 tumor-specific deaths out of 282 cases and 36 postoperative recurrences out of 282 cases. In the high-risk group, there were 19 tumor-specific deaths out of 54 cases and 33 post-operative recurrences out of 54 cases. There were significant differences in progression-free survival (PFS) and cancer-specific survival (CSS) between the low-risk and high-risk groups ( < 0.000 1).
A nomogram model predicting the 3-year CSS of non-metastatic T renal cell carcinoma patients was successfully constructed and validated in this study. This nomogram can assist clinicians in accurately assessing the long-term prognosis of such patients.
预测非转移性T期肾细胞癌患者术后3年癌症特异性生存率(CSS)。
回顾性收集2013年3月至2021年2月在北京大学第三医院泌尿外科接受手术治疗的336例经病理确诊的T N0-1M0肾细胞癌(RCC)患者。患者按4∶1比例随机分为268例的训练队列和68例的内部验证队列。采用双向套索回归选择变量,构建预测TN0-1M0 RCC患者3年癌症特异性生存率(CSS)的列线图。列线图的性能评估包括辨别力和校准能力评估,以及使用一致性指数(C指数)、受试者操作特征曲线的时间依赖性曲线下面积[时间依赖性曲线下面积(AUC)]、校准曲线和决策曲线分析(DCA)等指标进行临床实用性评估。根据列线图评分进行风险分层,采用Kaplan-Meier生存分析和Log-rank检验比较不同风险组患者的无进展生存期(PFS)和癌症特异性生存期(CSS)。
根据套索回归筛选结果,构建了包含肿瘤最大直径、组织学分级、肉瘤样分化、T特征和淋巴结转移5个变量的列线图。训练集和验证集的基线数据无统计学差异(>0.05)。训练集和内部验证集列线图的一致性指数分别为0.808(0.708-0.907)和0.903(0.838-0.969)。两组3年癌症特异性生存率的AUC值分别为0.843(0.725-0.961)和0.923(0.844-1.002)。两组的校准曲线均显示实际CSS与预测概率之间具有高度一致性。决策曲线分析(DCA)曲线表明列线图在临床实践中具有良好的净效益。本研究共纳入336例患者,其中35例癌症特异性死亡,69例术后复发。根据线图,患者分为低风险组(评分0-117)和高风险组(评分119-284)。低风险组282例中有16例肿瘤特异性死亡,282例中有36例术后复发。高风险组54例中有19例肿瘤特异性死亡,54例中有33例术后复发。低风险组和高风险组之间的无进展生存期(PFS)和癌症特异性生存期(CSS)存在显著差异(<0.000 1)。
本研究成功构建并验证了预测非转移性T期肾细胞癌患者3年CSS的列线图模型。该列线图可协助临床医生准确评估此类患者的长期预后。